Shire Withdraws European Application For DAYTRANA(TM) (Methylphenidate Transdermal System)
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has decided to withdraw the European Marketing Authorization Application (MAA) for DAYTRANA(TM) (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
More: continued here
Filed under: ADHD on March 29th, 2009
You must be logged in to post a comment.